We previously reported a milestone in the optimization of NBD-11021, an HIV-1 gp120 antagonist, by developing a new and novel analogue, NBD-14189 (Ref1), which showed antiviral activity against HIV-1HXB2, with a half maximal inhibitory concentration of 89 nM. However, cytotoxicity remained high, and the absorption, distribution, metabolism, and excretion (ADME) data showed relatively poor aqueous solubility. To optimize these properties, we replaced the phenyl ring in the compound with a pyridine ring and synthesized a set of 48 novel compounds. One of the new analogues, NBD-14270 (8), showed a marked improvement in cytotoxicity, with 3-fold and 58-fold improvements in selectivity index value compared with that of Ref1 and NBD-11021, respectively. Furthermore, the in vitro ADME data clearly showed improvements in aqueous solubility and other properties compared with those for Ref1. The data for 8 indicated that the pyridine scaffold is a good bioisostere for phenyl, allowing the further optimization of this molecule.
We previously reported a milestone in the optimization of NBD-11021, ann class="Species">HIV-1gp120 antagonist, by developing a new and novel analogue, NBD-14189 (Ref1), which showed antiviral activity against HIV-1HXB2, with a half maximal inhibitory concentration of 89 nM. However, cytotoxicity remained high, and the absorption, distribution, metabolism, and excretion (ADME) data showed relatively poor aqueous solubility. To optimize these properties, we replaced the phenyl ring in the compound with a pyridine ring and synthesized a set of 48 novel compounds. One of the new analogues, NBD-14270 (8), showed a marked improvement in cytotoxicity, with 3-fold and 58-fold improvements in selectivity index value compared with that of Ref1 and NBD-11021, respectively. Furthermore, the in vitro ADME data clearly showed improvements in aqueous solubility and other properties compared with those for Ref1. The data for 8 indicated that the pyridine scaffold is a good bioisostere for phenyl, allowing the further optimization of this molecule.
Authors: Cynthia A Derdeyn; Julie M Decker; Frederic Bibollet-Ruche; John L Mokili; Mark Muldoon; Scott A Denham; Marintha L Heil; Francis Kasolo; Rosemary Musonda; Beatrice H Hahn; George M Shaw; Bette T Korber; Susan Allen; Eric Hunter Journal: Science Date: 2004-03-26 Impact factor: 47.728
Authors: Maya Balamane; Vici Varghese; George L Melikian; W Jeffrey Fessel; David A Katzenstein; Robert W Shafer Journal: Antimicrob Agents Chemother Date: 2012-06-04 Impact factor: 5.191
Authors: Xiping Wei; Julie M Decker; Hongmei Liu; Zee Zhang; Ramin B Arani; J Michael Kilby; Michael S Saag; Xiaoyun Wu; George M Shaw; John C Kappes Journal: Antimicrob Agents Chemother Date: 2002-06 Impact factor: 5.191
Authors: Judith M LaLonde; Young Do Kwon; David M Jones; Alexander W Sun; Joel R Courter; Takahiro Soeta; Toyoharu Kobayashi; Amy M Princiotto; Xueling Wu; Arne Schön; Ernesto Freire; Peter D Kwong; John R Mascola; Joseph Sodroski; Navid Madani; Amos B Smith Journal: J Med Chem Date: 2012-04-23 Impact factor: 7.446
Authors: Francesca Curreli; Young Do Kwon; Hongtao Zhang; Daniel Scacalossi; Dmitry S Belov; Artur A Tikhonov; Ivan A Andreev; Andrea Altieri; Alexander V Kurkin; Peter D Kwong; Asim K Debnath Journal: J Med Chem Date: 2015-08-28 Impact factor: 7.446
Authors: Navid Madani; Arne Schön; Amy M Princiotto; Judith M Lalonde; Joel R Courter; Takahiro Soeta; Danny Ng; Liping Wang; Evan T Brower; Shi-Hua Xiang; Young Do Kwon; Chih-Chin Huang; Richard Wyatt; Peter D Kwong; Ernesto Freire; Amos B Smith; Joseph Sodroski Journal: Structure Date: 2008-11-12 Impact factor: 5.006
Authors: Francesca Curreli; Shahad Ahmed; Sofia M Benedict Victor; Ildar R Iusupov; Evgeny A Spiridonov; Dmitry S Belov; Andrea Altieri; Alexander V Kurkin; Asim K Debnath Journal: Bioorg Med Chem Date: 2021-01-08 Impact factor: 3.641